Congratulations to Anthony Vocat winner of the Short Oral Award 2025! His outstanding presentation, “Novel Mycobacteriophages as a Promising Adjunct in the Fight against Drug-Resistant TB and NTM Infections” captivated the scientific committee with its scientific rigor and real-world impact. His work highlights the innovative potential of bacteriophage therapy in addressing one of the most pressing global health challenges: drug-resistant tuberculosis and non-tuberculous mycobacterial infections.
About his Research and Future Steps:
The 37-year-old Swiss microbiologist with over a decade of experience in infectious disease research, particularly Mycobacterium tuberculosis pursues a PhD at CHUV / Centre hospitalier universitaire vaudois, under the supervision of Dr. Grégory Resch and Prof. Gilbert Greub within the CRISP group. His research focuses on discovering and characterizing new bacteriophages active against mycobacteria and Pseudomonas-related lung infections. The project includes isolating phages from environmental samples and developing ultra-rapid phage susceptibility testing (PST) using nanomotion technology, in collaboration with Resistell.”
Bravo Dr. Vocat for this well-deserved recognition and for pushing the boundaries of infectious disease research!
